Rearming the body’s immune system to fight cancer
We’re developing more precise and more accessible treatment alternatives for patients with solid cancers
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.
Some of our partners
Latest news
Patent office reopens major CRISPR battle between Broad Institute and Univ. of California
By Karen Loudon / July 3, 2019
STAT Biotech - By Sharon Begley @sxbegle JUNE 25, 2019 The U.S. patent office has declared an interference between a dozen...
Read More
Cartherics shareholders Thao and Luyen Nguyen at the June 2019 Board Meeting …….
By Karen Loudon / June 24, 2019
Cartherics shareholders Thao and Luyen Nguyen at the June 2019 Board Meeting with Cartherics Chairman Bob Moses and CEO Alan Trounson celebrating...
Read More
Australian Biotechnology “REALITIES” : From the Laboratory to the Marketplace
By Karen Loudon / June 7, 2019
Cartherics’ Chairman Bob Moses has over 40 years of executive experience in life science companies. You name it, he’s been...
Read More
